Google's subsidiary, ISomorphic Labs , by the end of 2025 will start clinical trials of artificial intelligence. This was reported by Demis Gassabis CEO, also known as Google Deepmind, and Nobel Prize in Chemistry Prize in 2024.
Isomorphic Labs is working on revolutionary methods of drug development, using AI to model chemical processes and optimize therapeutic formulas. According to Gassabis, the company focuses on oncology, cardiovascular diseases, neurodegenerative conditions and other important areas of medicine.
"We expect that by the end of the year we will get the first drug developed completely with the help of AI," Gassabis said during a speech at the World Economic Forum.
One of the main advantages of using AI in pharmaceuticals is the significant reduction in the time required to develop new drugs. If the traditional process of creating the drug takes from 5 to 10 years, then artificial intelligence is able to reduce this period by 10 times. This not only accelerates the appearance of innovations on the market, but also makes them more accessible to patients.
Gassabis also stressed that this technology has the potential to become a global health revolution, facilitating the development of more effective and personalized drugs.
Google and other companies in this field show that AI is gradually becoming an integral part of medical research. From predicting diseases to the creation of innovative drugs - artificial intelligence has the potential to transform approaches to the treatment of diseases.
The first test of the drug developed by AI will be an important step in confirming the efficiency and safety of new methods. If successful, this will open a new era in pharmaceuticals, allowing you to reduce research costs and implement solutions to treat complex diseases.
